IdyllaTM KRAS Mutation Assay (RUO)
A0021/6
The fully automated IdyllaTM KRAS Mutation Assay covers 21 KRAS mutations in exons 2,3 and 4 showing an excellent concordance to reference methods of >95%. Comparison with various other KRAS detecting technologies revealed a superior performance of the IdyllaTM KRAS Mutation Assay in terms of ease of use, turnaround time, and hands-on time while demonstrating superior levels of sensitivity.
For Research Use Only (RUO), not for use in diagnostic procedures.
For more information on the PlexZyme and PlexPrime licenses, click here.
Specimen requirements
One of the biggest challenges in oncology biomarker testing is the ability to obtain samples of sufficient size and quality. With the IdyllaTM System only a minimal amount of sample is needed
- 1x 5 μm FFPE tissue section -> 50-600 mm²
- 1x 10 μm FFPE tissue section -> 25-300 mm²
- Neoplastic cells ≥10% - if less, macrodissection is required
